With 78 of 80 Events Recorded, Sellas Life Sciences Attracts MassMutual Interest — and Weighs a $2.4 Billion Bet
Published on 07/08/2026 at 18:14 | Redaktion boerse-global.de
A new institutional backer has surfaced at Sellas Life Sciences just as the biotech firm's pivotal REGAL trial inches toward its final, decisive data readout. MassMutual, the U.S. insurance giant, has disclosed a stake in the clinical-stage company — a move that market participants often interpret as a precursor to major corporate developments. While Sellas has not confirmed any formal takeover talks, existing change-of-control provisions and recent comments from management have kept speculative whispers alive.
The stock, however, did not immediately celebrate the news. Shares slid 3.8% on Wednesday to €11.40, having closed at €11.85 the prior session. Even after that pullback, the equity has more than sextupled over the past twelve months, rising 540.45% — a rally that has pushed its market capitalization to an eye-popping €2.4 billion. Much of that optimism is priced into a price-to-book ratio of 23.4, dwarfing the sector average of 2.8 and the 8.6 median among comparable biotech peers.
The core catalyst remains the REGAL Phase 3 study, which is testing galinpepimut-S in acute myeloid leukemia. The trial requires 80 clinical events — specifically, patient deaths — for a final overall survival analysis. As of the first quarter of 2026, 78 of those events had been recorded. Sellas is effectively two cases away from the pivotal trigger. Analysts describe the upcoming data as a binary event that could send the stock soaring or sinking depending on the outcome.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
Retail traders are leaning heavily toward the bullish scenario. Their enthusiasm has kept the stock well above its 50-day moving average of €7.50, a 52.1% premium, and more than 193% above the 200-day average of €3.88. The 30-day annualized volatility stands at 126.71%, reflecting the extraordinary uncertainty that surrounds the trial's finish line. The relative strength index recently registered 61.2, a neutral-to-slightly-overbought reading that suggests the rally still has room to run — yet also highlights how stretched the valuation has become relative to the company's fundamentals.
That disconnect is not lost on institutional investors. Analysts peg the average price target at just €8.74, implying a sharp downside from current levels. The company posted a net loss of roughly $8.4 million in the first quarter of 2026, typical for a pre-revenue biotech, though it has taken steps to shore up liquidity through warrant exercises. At the end of March, cash and equivalents stood at $107.1 million, providing a runway that management hopes will fund a path to commercialization — but only if REGAL delivers positive results.
Sellas is also advancing a second candidate, SLS009, which showed efficacy in 93% of preclinical leukemia models. That pipeline prospect has provided additional support, but it remains a secondary storyline for now. The market's gaze is fixed squarely on those two remaining events. Every day that passes without a press release tightens the suspense for a company whose entire thesis — and its multibillion-dollar market tag — rests on a single binary outcome.
Ad
Sellas Life Sciences Stock: New Analysis - 8 July
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
